Do analysts prefer ZIVO or EDSA?

Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 35.99%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Edesa Biotech is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ZIVO or EDSA more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Edesa Biotech N/A -286.52% -75.36%

Do analysts recommend ZIVO or INKT?

MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 184.55%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MiNK Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40

Is ZIVO or INKT more profitable?

Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% MiNK Therapeutics N/A N/A -118.57%

Does the media favor ZIVO or INKT?

In the previous week, ZIVO Bioscience and ZIVO Bioscience both had 1 articles in the media. ZIVO Bioscience's average media sentiment score of 0.00 equaled MiNK Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZIVO Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiNK Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IMA or ZIVO?

ImageneBio currently has a consensus target price of $26.50, indicating a potential upside of 364.91%. Given ImageneBio's stronger consensus rating and higher probable upside, research analysts clearly believe ImageneBio is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImageneBio 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is IMA or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.96% -34.60% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts rate ZIVO or ANVS?

Annovis Bio has a consensus target price of $13.50, suggesting a potential upside of 686.71%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is ZIVO or ANVS more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Annovis Bio N/A -318.08% -215.47%

Do analysts prefer ZIVO or ENTX?

Entera Bio has a consensus price target of $9.00, suggesting a potential upside of 500.00%. Given Entera Bio's stronger consensus rating and higher possible upside, analysts clearly believe Entera Bio is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ZIVO or ENTX more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Entera Bio N/A -83.31% -70.83%

Does the media favor ZIVO or ENTX?

In the previous week, Entera Bio had 5 more articles in the media than ZIVO Bioscience. MarketBeat recorded 6 mentions for Entera Bio and 1 mentions for ZIVO Bioscience. Entera Bio's average media sentiment score of 0.40 beat ZIVO Bioscience's score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZIVO Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entera Bio 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ZIVO Bioscience (ZIVO) Competitors

$4.32 0.00 (0.00%)

As of 06/24/2026 12:59 PM Eastern

Compare

ZIVO vs. EDSA, INKT, IMA, ANVS, and ENTX

Should you buy ZIVO Bioscience stock or one of its competitors? MarketBeat compares ZIVO Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ZIVO Bioscience include Edesa Biotech (EDSA), MiNK Therapeutics (INKT), ImageneBio (IMA), Annovis Bio (ANVS), and Entera Bio (ENTX). These companies are all part of the "pharmaceutical products" industry.

How does ZIVO Bioscience compare to Edesa Biotech?

ZIVO Bioscience (NASDAQ:ZIVO) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

In the previous week, ZIVO Bioscience had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 1 mentions for ZIVO Bioscience and 0 mentions for Edesa Biotech. ZIVO Bioscience's average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Edesa Biotech	Neutral

ZIVO Bioscience's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Edesa Biotech	N/A	-286.52%	-75.36%

Edesa Biotech has lower revenue, but higher earnings than ZIVO Bioscience. Edesa Biotech is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,131.65	-$7.78M	-$1.71	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by company insiders. Comparatively, 24.4% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 35.99%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Edesa Biotech is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ZIVO Bioscience has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Summary

Edesa Biotech beats ZIVO Bioscience on 7 of the 13 factors compared between the two stocks.

How does ZIVO Bioscience compare to MiNK Therapeutics?

ZIVO Bioscience (NASDAQ:ZIVO) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

ZIVO Bioscience has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,131.65	-$7.78M	-$1.71	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 184.55%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
MiNK Therapeutics	N/A	N/A	-118.57%

ZIVO Bioscience has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, ZIVO Bioscience and ZIVO Bioscience both had 1 articles in the media. ZIVO Bioscience's average media sentiment score of 0.00 equaled MiNK Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ZIVO Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiNK Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ZIVO Bioscience and MiNK Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does ZIVO Bioscience compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

ZIVO Bioscience's return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
ZIVO Bioscience	N/A	N/A	-2,240.92%

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ZIVO Bioscience has lower revenue, but higher earnings than ImageneBio. ZIVO Bioscience is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	75.88	-$45.35M	-$5.79	N/A
ZIVO Bioscience	$15.85K	1,131.65	-$7.78M	-$1.71	N/A

In the previous week, ZIVO Bioscience had 1 more articles in the media than ImageneBio. MarketBeat recorded 1 mentions for ZIVO Bioscience and 0 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
ImageneBio	Neutral
ZIVO Bioscience	Neutral

ImageneBio currently has a consensus target price of $26.50, indicating a potential upside of 364.91%. Given ImageneBio's stronger consensus rating and higher probable upside, research analysts clearly believe ImageneBio is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ImageneBio has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market.

Summary

ImageneBio and ZIVO Bioscience tied by winning 7 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to Annovis Bio?

ZIVO Bioscience (NASDAQ:ZIVO) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

ZIVO Bioscience has higher revenue and earnings than Annovis Bio. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,131.65	-$7.78M	-$1.71	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

ZIVO Bioscience's return on equity of 0.00% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Annovis Bio	N/A	-318.08%	-215.47%

Annovis Bio has a consensus target price of $13.50, suggesting a potential upside of 686.71%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ZIVO Bioscience has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

In the previous week, ZIVO Bioscience had 1 more articles in the media than Annovis Bio. MarketBeat recorded 1 mentions for ZIVO Bioscience and 0 mentions for Annovis Bio. ZIVO Bioscience's average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Annovis Bio	Neutral

Summary

ZIVO Bioscience and Annovis Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does ZIVO Bioscience compare to Entera Bio?

ZIVO Bioscience (NASDAQ:ZIVO) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

ZIVO Bioscience's return on equity of 0.00% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Entera Bio	N/A	-83.31%	-70.83%

Entera Bio has a consensus price target of $9.00, suggesting a potential upside of 500.00%. Given Entera Bio's stronger consensus rating and higher possible upside, analysts clearly believe Entera Bio is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ZIVO Bioscience has higher earnings, but lower revenue than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,131.65	-$7.78M	-$1.71	N/A
Entera Bio	$40K	1,848.38	-$11.44M	-$0.27	N/A

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 10.6% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ZIVO Bioscience has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

In the previous week, Entera Bio had 5 more articles in the media than ZIVO Bioscience. MarketBeat recorded 6 mentions for Entera Bio and 1 mentions for ZIVO Bioscience. Entera Bio's average media sentiment score of 0.40 beat ZIVO Bioscience's score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ZIVO Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entera Bio	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Entera Bio beats ZIVO Bioscience on 11 of the 15 factors compared between the two stocks.

Get ZIVO Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZIVO vs. The Competition

Export

Metric	ZIVO Bioscience	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.94M	$350.40M	$6.74B	$12.32B
Dividend Yield	N/A	N/A	2.68%	5.88%
P/E Ratio	-0.89	N/A	25.13	23.95
Price / Sales	1,131.65	199.13	538.42	107.90
Price / Cash	N/A	22.44	45.29	53.76
Price / Book	-5.33	4.83	10.78	6.41
Net Income	-$7.78M	-$141.03M	$3.56B	$337.14M
7 Day Performance	17.07%	2.84%	0.99%	-1.07%
1 Month Performance	5.25%	-2.66%	0.80%	0.48%
1 Year Performance	-71.03%	61.70%	30.26%	28.42%

ZIVO Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZIVO ZIVO Bioscience	N/A	$4.32 flat	N/A	-71.0%	$17.94M	$15.85K	N/A	10	News Coverage Gap Down
EDSA Edesa Biotech	0.5958 of 5 stars	$7.35 +6.8%	$5.00 -32.0%	+297.5%	$61.18M	N/A	N/A	20	Positive News
INKT MiNK Therapeutics	2.9234 of 5 stars	$12.14 -0.6%	$35.00 +188.3%	+65.9%	$60.83M	N/A	N/A	30
IMA ImageneBio	1.7586 of 5 stars	$6.00 +5.4%	$26.50 +341.7%	-63.5%	$60.62M	$800K	N/A	70	Gap Down High Trading Volume
ANVS Annovis Bio	2.4343 of 5 stars	$1.77 +1.4%	$13.50 +664.9%	-44.2%	$60.29M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZIVO) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. EDSA, INKT, IMA, ANVS, and ENTX

How does ZIVO Bioscience compare to Edesa Biotech?

Summary

How does ZIVO Bioscience compare to MiNK Therapeutics?

Summary

How does ZIVO Bioscience compare to ImageneBio?

Summary

How does ZIVO Bioscience compare to Annovis Bio?

Summary

How does ZIVO Bioscience compare to Entera Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. EDSA, INKT, IMA, ANVS, and ENTX

How does ZIVO Bioscience compare to Edesa Biotech?

Does the media refer more to ZIVO or EDSA?

Is ZIVO or EDSA more profitable?

Which has preferable earnings & valuation, ZIVO or EDSA?

Do institutionals and insiders believe in ZIVO or EDSA?

Do analysts prefer ZIVO or EDSA?

Which has more volatility and risk, ZIVO or EDSA?

Summary

How does ZIVO Bioscience compare to MiNK Therapeutics?

Which has better valuation and earnings, ZIVO or INKT?

Do analysts recommend ZIVO or INKT?

Is ZIVO or INKT more profitable?

Which has more volatility and risk, ZIVO or INKT?

Do institutionals & insiders believe in ZIVO or INKT?

Does the media favor ZIVO or INKT?

Summary

How does ZIVO Bioscience compare to ImageneBio?

Is IMA or ZIVO more profitable?

Do institutionals and insiders hold more shares of IMA or ZIVO?

Which has stronger valuation & earnings, IMA or ZIVO?

Does the media refer more to IMA or ZIVO?

Do analysts rate IMA or ZIVO?

Which has more volatility and risk, IMA or ZIVO?

Summary

How does ZIVO Bioscience compare to Annovis Bio?

Which has preferable valuation & earnings, ZIVO or ANVS?

Is ZIVO or ANVS more profitable?

Do analysts rate ZIVO or ANVS?

Do institutionals & insiders hold more shares of ZIVO or ANVS?

Which has more volatility & risk, ZIVO or ANVS?

Does the media favor ZIVO or ANVS?

Summary

How does ZIVO Bioscience compare to Entera Bio?

Is ZIVO or ENTX more profitable?

Do analysts prefer ZIVO or ENTX?

Which has stronger earnings & valuation, ZIVO or ENTX?

Do institutionals and insiders have more ownership in ZIVO or ENTX?

Which has more risk & volatility, ZIVO or ENTX?

Does the media favor ZIVO or ENTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools